AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00555204
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg - capsules once daily for 12 weeks
Trial: NCT00555204
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo - capsules once daily for 12 weeks
Trial: NCT00799136
Drug: R-EPOCH and cART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
Trial: NCT03665753
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject will receive 10, 20, and 30mg of Ketorolac.
Trial: NCT00002760
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective
Trial: NCT01871558
Drug: sulfonylurea (SU)
RxNorm normalized name: sulfanilylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04112641
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral ingestion of placebo in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
Trial: NCT04317001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01892891
Drug: VBY-036
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathepsin S inhibitor
Trial: NCT03598725
Drug: Coagulation Factor VIII
RxNorm normalized name: Coagulation factor VIII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domastic plasma derived factor FVIII (with intermidiate vWF) 50IU/kg every other day
Trial: NCT02629120
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Post transplant cyclophosphamide given to prevent graft verses host disease. This is a well studied drug, and is not under an IND.
Trial: NCT01627782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.
Trial: NCT02040558
Drug: MNK-010
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003640
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02281526
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00171873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chloride intramuscularly every 28 days
Trial: NCT03092245
Drug: OctaplasLG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OctaplasLG is given as an infusion when resuscitation fluids are required.
Trial: NCT01120288
Drug: EZN-2968
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001721
Drug: Cholesterol Suspension
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00671398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo-matching tablets, orally for one night only
Trial: NCT00880308
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01897831
Drug: xin te mie
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: durg:Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) 1.5-3.0g,iv,bid for 7-14 days Serious infections:6.0-12.0g,iv,tid for 7-14 days
Trial: NCT03235219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Trial: NCT00942981
Drug: PET
RxNorm normalized name: PETN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain dopamine D1 and D2/3 receptor regional binding potentials measured by \[11C\]NNC-112 and \[18F\]Fallypride PET.
Trial: NCT03700450
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
Trial: NCT02944656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this group will receive 600 mg of gelatin capsules that are identical in appearance to gabapentin capsules. The placebo will be given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion.
Trial: NCT04376827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo IV at Weeks 0, 4 and 8 (that is, 3 IV doses) and placebo SC q4w from Week 12 through Week 48.
Trial: NCT01804673
Drug: Fentanyl-ITS
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl Iontophoretic Transdermal (through the skin) System (ITS) will release fentanyl at the rate of 40 microgram (mcg) (1 dose) to maximum of 240 mcg per hour (6 doses) but not more than 3.2 milligram (mg) (80 doses) per 24 hours. The duration of study treatment will be 72 hours.
Trial: NCT03796026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
Trial: NCT04036500
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given estradiol: 1 mg oral and 1 mg sublingual.
Trial: NCT00082199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, Once daily, 12 weeks.
Trial: NCT02277444
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate BSA-based dose (10 to 30 mg/m\^2 per week for participants with BSA \<1.67 m\^2, or minimum of 15 mg/week for participants with BSA \>=1.67 m\^2) weekly at least through Week 28.
Trial: NCT03236987
Drug: Clarithromycin 1000 MG
RxNorm normalized name: clarithromycin 1000 MG
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.
Trial: NCT03236987
Drug: Azithromycin 250 mg
RxNorm normalized name: azithromycin 250 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.
Trial: NCT03301233
Drug: estradiol valerate and sildenafil
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (45 women will receive clomiphene citrate (clomid 50mg ®, Sanofi aventis) 2 tab. single dose orally from the 2nd day of the cycle for 5 days with oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
Trial: NCT03922724
Drug: IOC
RxNorm normalized name: Biocef
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e-ATG40 mg/kg/day IV on days -14 and -13. Pentostatin 4 mg/m2/day IV on days -9 and -5. Cyclophosphamide 5 mg/kg orally daily on days -9 through -2
Trial: NCT03992846
Drug: Placebo capsule to match Add-back capsule
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For oral administration once daily
Trial: NCT03114371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo should be used as a spray, similar to that of the oxytocin. The dosage administered will be 1 spray in each nostril per day for the first 12 weeks in 3 to 6 years old patients. The dosage administered will be 2 sprays in each nostril per day for the first 12 weeks, in 7 to 12 years old patients.
Trial: NCT03401268
Drug: subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 patients demonstrating hypogammaglobulinemia post allogeneic HCT will be started on ScIG for a total of 6 months. Tolerability of the intervention will be assessed with qualitative questionnaires, as well as a financial analysis regarding the intervention.
Trial: NCT03993236
Drug: Experimental: Rosuvastatin/Ezetimibe 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Rosuvastatin/Ezetimibe 10/10mg~* orally administered once daily for 90 days
Trial: NCT03993236
Drug: Active Comparator: Rosuvastatin 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Rosuvastatin 20mg~* orally administered once daily for 90 days
Trial: NCT01493960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal dose at week 0 and 4
Trial: NCT01742637
Drug: Epiduo® Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)applied topically once daily for 84 consecutive days.
Trial: NCT01742637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
Trial: NCT04551196
Drug: Alternating Acetaminophen and Ibuprofen
RxNorm normalized name: acetaminophen / ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will alternate their post-operative acetaminophen and ibuprofen every 3 hours.
Trial: NCT04551196
Drug: Combined Acetaminophen and Ibuprofen
RxNorm normalized name: acetaminophen / ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take their post-operative acetaminophen and ibuprofen together every 6 hours.
Trial: NCT00325546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00659594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02357290
Drug: Open-label Treatment with N-Acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02254408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally or via nasogastric tube
Trial: NCT00981474
Drug: blood pressure maintenance based on cerebral blood flow autoregulation measurement
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure lowered or raised
Trial: NCT01401413
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo control i pill nightly for 30 nights
Trial: NCT00172120
Drug: ALX1-11
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03815084
Drug: pd-1 and DC-NK cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 .
Trial: NCT00487734
Drug: Placebo for testosterone gel
RxNorm normalized name: testosterone Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel, 2.5g for each gel packet
Trial: NCT01993017
Drug: Antidepressant Medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.~Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated.
Trial: NCT01161472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic
Trial: NCT01619332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
Trial: NCT01619332
Drug: LEZ763
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
Trial: NCT03117725
Drug: Melatonin adminstration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug, melatonin will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: Melatonin 2mg once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
Trial: NCT00239070
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03117725
Drug: placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the drug, placebo pill will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: placebo pill once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
Trial: NCT04233502
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: prolonged release 1 mg and 5 mg mini-tablets coated odorless and tasteless to facilitate swallowing
Trial: NCT04233502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo melatonin
Trial: NCT04353817
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet for oral administration qd in the morning.
Trial: NCT01136213
Drug: Fluoxétine / Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
Trial: NCT04430790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose and continuous placebo infusion.
Trial: NCT00303160
Drug: vitamin C & E supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02222961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02415777
Drug: Ursodeoxycholic acid, thiamine, riboflavin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00401635
Drug: liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00603265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02299804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active ingredient
Trial: NCT01207323
Drug: MEHD7945A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEHD7945A will be administered as specified in the individual arms.
Trial: NCT01919996
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
Trial: NCT00602680
Drug: SSR180711C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: duration of treatment: 4 weeks
Trial: NCT00602680
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: duration of treatment: 4 weeks
Trial: NCT03600896
Drug: CYT107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: Patients will be treated with CYT107 post CBT (from 60 to 180 days), in with 1 of 3 doses below:~* 5 mcg/kg/dose for 3 doses~* 10 mcg/kg/dose for 3 doses~* 20 mcg/kg/dose for 3 doses~The optimal recommended dose determined in Phase I will be used to treat all patient enrolled in Phase II.
Trial: NCT00953212
Drug: beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol 25mg by mouth every 6 hours
Trial: NCT00986362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravitreal injection
Trial: NCT00953212
Drug: ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days
Trial: NCT01299298
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug
Trial: NCT02965053
Drug: EOS789
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02965053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00172042
Drug: Zoledronic acid 4 mg
RxNorm normalized name: zoledronic acid 4 MG
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
Trial: NCT04189640
Drug: Postoperative analgesia management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure. If the VAS score will be ≥ 4, 0.5 mg/ kg tramadol IV will be administered.
Trial: NCT02608905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
Trial: NCT00328640
Drug: Optimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00888901
Drug: corticosteroids (Aprednislon)
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: corticosteroids in decreasing dosage
Trial: NCT02100150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strawberry flavored solution 0.5% v/v in Water for Injection
Trial: NCT00928512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
Trial: NCT00086294
Drug: Intravenous Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00086294
Drug: ACP-103
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02585596
Drug: YH23537 1000mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH23537 500mg 2 tab
Trial: NCT02585596
Drug: YH23537 2000mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH23537 500mg 4 tab
Trial: NCT02585596
Drug: YH23537 3000mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH23537 500mg 6 tab
Trial: NCT02585596
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH23537 500mg tab placebo
Trial: NCT02661503
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02661503
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00084643
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT03202095
Drug: Creatine Monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 grams daily of oral creatine monohydrate powder.
Trial: NCT03126214
Drug: Anticoagulants
RxNorm normalized name: ANTICOAGULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.
Trial: NCT03170193
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of matching placebo by SC or IV injection
Trial: NCT02901483
Drug: PEP503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEP503 will be administered by intratumoral route as slow injection
Trial: NCT03539367
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Trial: NCT00296023
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes